Viz.ai, a leader in AI-driven healthcare solutions, has pulled in a $100 million Series D round to bring its valuation to $1.2 billion. The raise follows a pivotal FDA clearance earlier in the year for its AI-driven aneurysm-spotting program. The company has also launched similar solutions capable of identifying aortic disease and pulmonary embolisms with AI. Another of its programs – currently under FDA review – aims to spot subdural hematomas.
The round was led by Insight Partners and Tiger Global, with supplemental funding from Kleiner Perkins, Threshold, GV, CRV, Susa, Scale Ventures, and Sozo Ventures. The money will help Viz.ai follow through on its ambitions to develop programs for additional conditions. “We will continue to invest heavily in cutting-edge technology and services to integrate deeply into the clinical workflow, allowing us to automate disease detection, increase diagnostic rates, and enhance workflows across the entire hub and spoke health system,” said Viz.ai Co-founder and Chief Executive Officer Chris Mansi.
The raise comes in the wake of the company reaching a milestone 1,000-hospital adoption of its platform for reading and triaging CT scans, as well as a significant commercial expansion into Africa, the Middle East, and Europe. In a year’s time, the Viz.ai employee count has risen from 180 to more than 350, and an additional 200 hires are planned for the next 12 months.